Indian Journal of Sleep Medicine

Register      Login

VOLUME 2 , ISSUE 1 ( January-March, 2007 ) > List of Articles

ORIGINAL ARTICLE

CRP and Metabolic Syndrome in Obstructive Sleep Apnea

Babak Amra, Hematollah Babaie, Mohammad Golshan

Citation Information : Amra B, Babaie H, Golshan M. CRP and Metabolic Syndrome in Obstructive Sleep Apnea. Indian Sleep Med 2007; 2 (1):28-31.

DOI: 10.5005/ijsm-2-1-28

License: CC BY-SA 4.0

Published Online: 01-01-2007

Copyright Statement:  Copyright © 2007; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract


PDF Share
  1. Mooe T, Franklin KA, Holmstrom K, Rabben T, Wiklund U:Sleep-disordered breathing and coronary artery disease: long term prognosis. Am J Respir Crit Care Med 2001; 164: 1910–1913.
  2. Milleron O, Pilliere R, Foucher A, et al: Benefits of obstructive sleep apnoea treatment in coronary artery disease: a longterm follow-up study. Eur Heart J 2004; 25: 728–734.
  3. Shepertycky MR, Al-Barrak M, Kryger MH: Mobidity and mortality in obstructive sleep apnea syndrome 1: effect of treatment on cardiovascular morbidity. Sleep Biol Rhythms 2003; 1: 15–28.
  4. Budhiraja R, Sharief I, Quan SF: Sleep disordered breathing and hypertension. J Clin Sleep Med 2005; 1: 401–404.
  5. Lakka HM, Laaksonen DE, Lakka TA, et al: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709–2716.
  6. Malik S, Wong ND, Franklin SS, et al: Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 101: 1239–1244.
  7. Takeuchi H, Saitoh S, Takagi S, et al: Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program”Adult Treatment Panel III to Japanese men
  8. Wolk R, Shamsuzzaman AS, Somers VK: Obesity, sleep apnea, and hypertension. Hypertension 2003; 42: 1067– 1074.
  9. Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM, Wilding JP: Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J 2004; 25: 735–741.
  10. Glass CK, Witztum JL: Atherosclerosis. The road ahead. Cell 2001; 104: 503–516.
  11. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL: Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004; 109 (Suppl 1): IV6–IV19.
  12. Danesh J, Wheeler JG, Hirschfield GM, et al: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350: 1387–1397.
  13. Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al: Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 2002; 105: 2462–2464.
  14. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42–47.
  15. McArdle N, Hillman D, Beilin L, Watts G: Metabolic risk factors for vascular disease in obstructive sleep apnea: A matched controlled study. Am J Respir Crit Care Med 2007;175 : 190-195
  16. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285(19):2486–2497.
  17. Rechtshaffen A, Kales A (eds): A Manual of Standardized Terminology: Techniques and Scoring System for Sleep Stages of Human Subjects. Los Angeles, UCLA Brain Information Service/Brain Research Institute, 1968.
  18. American Academy of Sleep Medicine Task Force: Sleep related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The report of an American Academy of Sleep Medicine Task Force. Sleep 1999; 22: 667–689.
  19. Doelle GC: The clinical picture of metabolic syndrome. An update on this complex of conditions and risk factors. Postgrad Med 2004; 116: 30–38.
  20. Jialal I, Devaraj S, Venugopal SK: C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004; 44: 6–11.
  21. Calabro P, Willerson JT, Yeh ET: Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003; 108:1930– 1932.
  22. Sattar N, Gaw A, Scherbakova O, et al: Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108: 414– 419.
  23. Pannacciulli N, Cantatore FP, Minenna A, Bellacicco M, Giorgino R, De Pergola G: C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women. Int J Obes Relat Metab Disord 2001; 25: 1416–1420.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.